Bristol Reyataz Dosing For Renally-Impaired Patients Will Be Phase IV Study
Executive Summary
FDA is requesting that Bristol-Myers Squibb determine appropriate Reyataz dosing for patients with renal impairment in a Phase IV study
You may also be interested in...
Bristol Reyataz To Launch In July; Lipid Data Included In Labeling
Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment
Reyataz Lipid Effect Offers Benefit But Not In Lipodystrophy, Cmte. Says
The favorable lipid profile of Bristol-Myers Squibb's protease inhibitor Reyataz offers HIV patients a clinical benefit over other protease inhibitors, FDA's Antiviral Drugs Advisory Committee agreed May 14
Bristol Reyataz Gets Broad Label Vote Despite Concerns In Drug Experienced
Bristol-Myers Squibb's protease inhibitor Reyataz is on track for a June approval with a broad label recommendation following a positive advisory committee review May 13